Table 4.

Cox proportional hazard models for ad hoc analysis

Reference group	Fully adjusted HRs (95% CI)
	For progression from unmedicated baseline diabetes to use of oral antidiabetic therapy	For progression from baseline use of oral antidiabetic therapy to use of insulin
All fibrate users	0.54 (0.38–0.76)	0.78 (0.55–1.10)
Ciprofibrate users	0.44 (0.28–0.69)	0.78 (0.50–1.22)
Fenofibrate users	0.57 (0.32–1.02)	0.86 (0.52–1.42)
Gemfibrozil users	0.74 (0.38–1.43)	0.57 (0.31–1.05)

All models treat bezafibrate as the exposure; reference group varies by row. Clofibrate was not used alone as a reference group because of an insufficient number of observations in the clofibrate group to support multivariable modeling. Fully adjusted models are adjusted for year of treatment initiation, age, sex, history of congestive heart failure, history of stroke, and history of drug use (ACE/angiotensin receptor blocker, calcium channel blocker, loop diuretic, thiazide diuretic, β-blocker, or steroid).